JNJ 39758979|JNJ-39758979;JNJ39758979

Cas No.:	1046447-90-8
Chemical Name:	JNJ-39758979
Synonyms:	JNJ-39758979;jnj39758979;4-[(3R)-3-AMINOPYRROLIDIN-1-YL]-6-PROPAN-2-YLPYRIMIDIN-2-AMINE;JNJ 39758979 (JNJ-39758979;2-Pyrimidinamine, 4-[(3R)-3-amino-1-pyrrolidinyl]-6-(1-methylethyl)-;(R)-4-(3-aminopyrrolidin-1-yl)-6-isopropylpyrimidin-2-amine;agranulocytosis,histamine,JNJ-39758979,selective,toxicity,JNJ39758979,cAMP,inhibit,oral,Histamine Receptor,anti-inflammatory,Inhibitor,antipruritic,JNJ 39758979;MFCD28502028;MFCD28502028;JNJ-39758979, (-)-;JNJ-39758979, (-)-;4-((3R)-3-aminopyrrolidin-1-yl)-6-propan-2-ylpyrimidin-2-amine;4-((3R)-3-aminopyrrolidin-1-yl)-6-propan-2-ylpyrimidin-2-amine;CS-0020957;CS-0020957;BDBM50006789;BDBM50006789;1046447-90-8;1046447-90-8;JNJ 39758979 [WHO-DD];JNJ 39758979 [WHO-DD];2-Pyrimidinamine, 4-((3R)-3-amino-1-pyrrolidinyl)-6-(1-methylethyl)-;2-Pyrimidinamine, 4-((3R)-3-amino-1-pyrrolidinyl)-6-(1-methylethyl)-;4-[(3R)-3-aminopyrrolidin-1-yl]-6-propan-2-ylpyrimidin-2-amine;4-[(3R)-3-aminopyrrolidin-1-yl]-6-propan-2-ylpyrimidin-2-amine;GLXC-04851;GLXC-04851;WRB44790;WRB44790;MS-23237;MS-23237;SCHEMBL604514;SCHEMBL604514;JNJ 39758979;JNJ 39758979;(r)-4-(3-amino-pyrrolidin-1-yl)-6-isopropyl-pyrimidin-2-ylamine;(r)-4-(3-amino-pyrrolidin-1-yl)-6-isopropyl-pyrimidin-2-ylamine;4-[(3R)-3-aminopyrrolidin-1-yl]-6-isopropylpyrimidin-2-amine;4-[(3R)-3-aminopyrrolidin-1-yl]-6-isopropylpyrimidin-2-amine;HY-101189;HY-101189;GTPL8984;GTPL8984;UNII-5RV7T5BNMG;UNII-5RV7T5BNMG;Q27888282;Q27888282;JNJ-39758979 [WHO-DD];JNJ-39758979 [WHO-DD];4-[(3R)-3-aminopyrrolidin-1-yl]-6-(propan-2-yl)pyrimidin-2-amine;4-[(3R)-3-aminopyrrolidin-1-yl]-6-(propan-2-yl)pyrimidin-2-amine;AKOS030628488;AKOS030628488;5RV7T5BNMG;5RV7T5BNMG;CHEMBL3236549;CHEMBL3236549
SMILES:	C1(N)=NC(C(C)C)=CC(N2CC[C@@H](N)C2)=N1
Formula:	C₁₁H₁₉N₅
M.Wt:	221.302061319351
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

A potent, selective, orally bioavailable histamine H4 receptor antagonist with Ki of 12.5 nM, >80-fold selectivity over other histamine receptors; shows dose-dependent activity in models of asthma and dermatitis, has good pharmacokinetics.AsthmaPhase 2 Clinical

MSDS

COA

LOT NO.	DOWNLOAD

2018-0101

Cat. No.	Product name	Field of application
DC31074	Isopropyl myristate	Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC75868	AZ14133346	AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865	TI17	TI17 represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.
DC75816	Nisoxetine	Nisoxetine acts as a highly selective and potent noradrenaline transporter (NET) antagonist, exhibiting a binding affinity (Kd) of 0.76 nM. In addition to its antidepressant properties, nisoxetine functions as a local anesthetic by inhibiting voltage-gated sodium channels. This dual pharmacological activity makes it a compound of interest for both neurological and pain management research.
DC75641	GENZ-644282 TFA salt	Genz-644282, also known as SAR402674, is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibits the enzyme topoisomerase I, which may result in the inhibition of repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations.
DC75325	PSMA-617 TFA	PSMA-617, also know as vipivotide tetraxetan, is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA617 possesses a small peptide, which was designed to target prostate-specific membrane antigen (PSMA). PSMA617 demonstrates high radiolytic stability for at least 72 h. PSMA617 has high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined). 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC.
DC75202	Fosaprepitant free acid	Fosaprepitant, also known as MK0517, is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4
DC74748	O4I4	O4I4 (compound 23) is a OCT4-inducing compound with metabolical stability.
DC74684	ZH8667	ZH8667 is a trace amine-associated receptor 1 (TAAR1)–Gs agonist.
DC74646	EB-PSMA-617	EB-PSMA-617 is an Evans blue-modified prostate-specific membrane antigen (PSMA) 617 ligand for making 177Lu-EB-PSMA, which is potential useful for Metastatic Castration-Resistant Prostate Cancer.